Download PDF
Pharmacopsychiatry 2021; 54(01): 31-35
DOI: 10.1055/a-1221-5293
Original Paper

Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample

Georgios Schoretsanitis 
1   The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA
,
Ekkehard Haen 
2   Clinical Pharmacology, Department of Psychiatry and Psychotherapy and Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany
,
Andreas Conca
3   Servizio Psichiatrico del Comprensorio Sanitario di Bolzano, Bolzano, Italy
,
Daria Piacentino
4   Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, The National Institutes of Health, Bethesda, USA
,
Florian Ridders
1   The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA
,
Christoph Hiemke
5   Department of Psychiatry and Psychotherapy and Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Germany
,
Gerhard Gründer
6   Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
,
Michael Paulzen
7   Alexianer Hospital Aachen, Aachen, Germany, and Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, and JARA – Translational Brain Medicine, Aachen, Germany
› Author Affiliations Funding Information: This research did not receive any funding.
› Further Information
Also available at
    Permissions and Reprints

Abstract

Introduction Major smoking effects have been reported for a series of psychotropic agents, mainly including substrates of CYP450 1A2, although smoking may also affect alternative metabolic pathways. To our knowledge, smoking effects on paliperidone pharmacokinetics have not been assessed yet.

Methods We compared plasma concentrations of paliperidone as well as dose-corrected-plasma concentrations (C/D) from a naturalistic database between smokers and nonsmokers using nonparametrical tests, such as the Mann-Whitney U-test (MWU). Additionally, we compared light and heavy smokers with nonsmokers separately.

Results Comparing 55 smokers with 37 nonsmokers treated with oral paliperidone, no differences in the percentage of females, age, body weight, body mass index, and daily paliperidone dose were reported (p=0.709 for χ2, p=0.26, p=0.38, p=0.67, and p=0.8 for MWU). No differences were detected in plasma concentrations or C/D values (p=0.50 and p=0.96 for MWU). Likewise, differences in daily dose, plasma concentrations, or C/D values were not significant between light smokers (n=17) and nonsmokers (p=0.61, p=0.81, and p=0.33 for MWU) or heavy smokers (n=22) and nonsmokers (p=0.874, p=0.38, and p=0.59; MWU in all cases).

Discussion Paliperidone is not affected by smoking, and paliperidone dose-adjustments in smokers may not be necessary. This may be seen as an essential difference to risperidone, whose cytochrome-mediated metabolism might be affected by smoking.

Key words

Pharmacokinetics - Antipsychotic drugs - Schizophrenia treatment


Publication History

Received: 18 June 2020
Received: 11 May 2020

Accepted: 09 July 2020

Article published online:
06 August 2020

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Gage SH, Munafo MR. Rethinking the association between smoking and schizophrenia. Lancet Psychiatry 2015; 2: 118-119
    CrossrefPubMedGoogle Scholar
  • 2 Cook BL, Wayne GF, Kafali EN. et al. Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA 2014; 311: 172-182
    CrossrefPubMedGoogle Scholar
  • 3 Liang Y, Huang J, Tian J. et al. The prevalence and risk factors of stroke in patients with chronic schizophrenia. Neuropsychiatr Dis Treat 2016; 12: 1131-1134
    CrossrefPubMedGoogle Scholar
  • 4 Krieger I, Tzur Bitan D, Comaneshter D. et al. Increased risk of smoking-related illnesses in schizophrenia patients: a nationwide cohort study. Schizophr Res 2019; 212: 121-125
    CrossrefPubMedGoogle Scholar
  • 5 Freeman TP, Stone JM, Orgaz B. et al. Tobacco smoking in schizophrenia: investigating the role of incentive salience. Psychol Med 2014; 44: 2189-2197
    CrossrefPubMedGoogle Scholar
  • 6 Fang Y, Wang W, Zhu C. et al. Use of tobacco in schizophrenia: A double-edged sword. Brain Behav 2019; 9: e01433
    CrossrefPubMedGoogle Scholar
  • 7 Augustin M, Schoretsanitis G, Hiemke C. et al. Differences in duloxetine dosing strategies in smoking and nonsmoking patients: Therapeutic drug monitoring uncovers the impact on drug metabolism. J Clin Psychiatry 2018; 79: 17m12086
    CrossrefPubMedGoogle Scholar
  • 8 Augustin M, Schoretsanitis G, Pfeifer P. et al. Effect of fluvoxamine augmentation and smoking on clozapine serum concentrations. Schizophr Res 2019; 210: 143-148
    CrossrefPubMedGoogle Scholar
  • 9 Kuzin M, Schoretsanitis G, Haen E. et al. The effects of co-prescription of pantoprazole on the clozapine metabolism. Pharmacopsychiatry 2019; 53: 65-70
    PubMedGoogle Scholar
  • 10 Djordjevic N, Radmanovic B, Cukic J. et al. Cigarette smoking and heavy coffee consumption affecting response to olanzapine: The role of genetic polymorphism. World J Biol Psychiatry 2020; 21: 29-52
    CrossrefPubMedGoogle Scholar
  • 11 Zevin S, Benowitz NL. Drug interactions with tobacco smoking. An update. Clin Pharmacokinet 1999; 36: 425-438
    CrossrefPubMedGoogle Scholar
  • 12 McCarthy RH. Seizures following smoking cessation in a clozapine responder. Pharmacopsychiatry 1994; 27: 210-211
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Derenne JL, Baldessarini RJ. Clozapine toxicity associated with smoking cessation: case report. Am J Ther 2005; 12: 469-471
    CrossrefPubMedGoogle Scholar
  • 14 Meyer JM. Individual changes in clozapine levels after smoking cessation: results and a predictive model. J Clin Psychopharmacol 2001; 21: 569-574
    CrossrefPubMedGoogle Scholar
  • 15 Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004; 76: 178-184
    CrossrefPubMedGoogle Scholar
  • 16 Suzuki Y, Sugai T, Fukui N. et al. CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. J Psychopharmacol 2011; 25: 908-914
    CrossrefPubMedGoogle Scholar
  • 17 Haslemo T, Eikeseth PH, Tanum L. et al. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006; 62: 1049-1053
    CrossrefPubMedGoogle Scholar
  • 18 Mayerova M, Ustohal L, Jarkovsky J. et al. Influence of dose, gender, and cigarette smoking on clozapine plasma concentrations. Neuropsychiatr Dis Treat 2018; 14: 1535-1543
    CrossrefPubMedGoogle Scholar
  • 19 Rahmioglu N, Heaton J, Clement G. et al. Genetic epidemiology of induced CYP3A4 activity. Pharmacogenet Genomics 2011; 21: 642-651
    CrossrefPubMedGoogle Scholar
  • 20 Kang D, Verotta D, Krecic-Shepard ME. et al. Population analyses of sustained-release verapamil in patients: Effects of sex, race, and smoking. Clin Pharmacol Ther 2003; 73: 31-40
    CrossrefPubMedGoogle Scholar
  • 21 Scherf-Clavel M, Deckert J, Menke A. et al. Smoking is associated with lower dose-corrected serum concentrations of escitalopram. J Clin Psychopharmacol 2019; 39: 485-488
    CrossrefPubMedGoogle Scholar
  • 22 Schoretsanitis G, Haen E, Stegmann B. et al. Effect of smoking on risperidone pharmacokinetics—a multifactorial approach to better predict the influence on drug metabolism. Schizophr Res 2017; 185: 51-57
    CrossrefPubMedGoogle Scholar
  • 23 Petros WP, Younis IR, Ford JN. et al. Effects of tobacco smoking and nicotine on cancer treatment. Pharmacotherapy 2012; 32: 920-931
    CrossrefPubMedGoogle Scholar
  • 24 Schoretsanitis G, Spina E, Hiemke C. et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. Expert Rev Clin Pharmacol 2017; 10: 965-981
    CrossrefPubMedGoogle Scholar
  • 25 Schoretsanitis G, Spina E, Hiemke C. et al. A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. Expert Rev Clin Pharmacol 2018; 11: 625-639
    CrossrefPubMedGoogle Scholar
  • 26 Corena-McLeod M. Comparative pharmacology of risperidone and paliperidone. Drugs R D 2015; 15: 163-174
    CrossrefPubMedGoogle Scholar
  • 27 Vermeir M, Naessens I, Remmerie B. et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008; 36: 769-779
    CrossrefPubMedGoogle Scholar
  • 28 Hiemke C, Bergemann N, Clement HW. et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018; 51: 9-62
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Paulzen M, Haen E, Stegmann B. et al. Clinical response in a risperidone-medicated naturalistic sample: Patients’ characteristics and dose-dependent pharmacokinetic patterns. Eur Arch Psychiatry Clin Neurosci 2017; 267: 325-333
    CrossrefPubMedGoogle Scholar
  • 30 Schoretsanitis G, Haen E, Hiemke C. et al. Risperidone-induced extrapyramidal side effects: Is the need for anticholinergics the consequence of high plasma concentrations?. Int Clin Psychopharmacol 2016; 31: 259-264
    CrossrefPubMedGoogle Scholar
  • 31 Schoretsanitis G, Stegmann B, Hiemke C. et al. Pharmacokinetic patterns of risperidone-associated adverse drug reactions. Eur J Clin Pharmacol 2016; 72: 1091-1098
    CrossrefPubMedGoogle Scholar
  • 32 Feng Y, Pollock BG, Coley K. et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol 2008; 66: 629-639
    PubMedGoogle Scholar
  • 33 Bowskill SV, Handley SA, Fisher DS. et al. Risperidone and total 9-hydroxyrisperidone in relation to prescribed dose and other factors: Data from a therapeutic drug monitoring service, 2002–2010. Ther Drug Monit 2012; 34: 349-355
    CrossrefPubMedGoogle Scholar
  • 34 Fischer-Barnicol D, Lanquillon S, Haen E. et al. Typical and atypical antipsychotics—the misleading dichotomy. Results from the Working Group “Drugs in Psychiatry” (AGATE). Neuropsychobiology 2008; 57: 80-87
    CrossrefPubMedGoogle Scholar
  • 35 US Food & Drug Administration Drug development and drug interactions: Table of substrates, inhibitors and inducers. 2014; [Last accessed: 05/11/2020]
  • 36 Bader W, Melchner D, Nonenmacher T. et al. Determination of five commonly used antipsychotics in human serum by high performance-liquid chromatography (HPLC) and electrochemical detection. Pharmacopsychiatry 2005; 38: 4
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Paul L, Musshoff F, Aebi B. et al. Richtlinie der GTFCh zur Qualitätssicherung bei forensisch-toxikologischen Untersuchungen. Toxichem Krimtech 2009; 76: 142-176
    PubMedGoogle Scholar
  • 38 US Food & Drug Administration Guidance for industry on biomedical method validation. 2001; [Last accessed: 05/11/2020]
  • 39 Schoretsanitis G, Haen E, Grunder G. et al. Pharmacokinetic drug-drug interactions of mood stabilizers and risperidone in patients under combined treatment. J Clin Psychopharmacol 2016; 36: 554-561
    CrossrefPubMedGoogle Scholar
  • 40 de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010; 51: 80-88
    CrossrefPubMedGoogle Scholar
  • 41 Paulzen M, Orfanos S, Grunder G. Remission of drug-induced hepatitis after switching from risperidone to paliperidone. Am J Psychiatry 2010; 167: 351-352
    CrossrefPubMedGoogle Scholar
  • 42 Suzuki H, Gen K, Otomo M. et al. Relationship between the plasma concentration of paliperidone and the clinical and drug-induced extrapyramidal symptoms in elderly patients with schizophrenia. Hum Psychopharmacol 2014; 29: 244-250
    CrossrefPubMedGoogle Scholar
  • 43 Paulzen M, Haen E, Gründer G. et al. Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients—thinking of clinically relevant CYP2D6 interactions. J Psychopharmacol 2016; 30: 803-809
    CrossrefPubMedGoogle Scholar
  • 44 Tantcheva-Poor I, Zaigler M, Rietbrock S. et al. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999; 9: 131-144
    PubMedGoogle Scholar
  • 45 Schoretsanitis G, Spina E, Hiemke C. et al. A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. Expert Rev Clin Pharmacol 2018; 11: 1237-1253
    CrossrefPubMedGoogle Scholar
  • 46 Schoretsanitis G, de Leon J, Eap CB. et al. Clinically significant drug-drug interactions with agents for attention-deficit/hyperactivity disorder. CNS Drugs 2019; 33: 1201-1222
    CrossrefPubMedGoogle Scholar